The spin-off would allow Novartis' shareholders "to participate fully in the potential future upside of both Sandoz and Novartis Innovative Medicines," said the company in a statement. As it ...

With a separation from parent company Novartis now confirmed, Sandoz has moved to strengthen ... at the helm of the business following the spin-off, which is scheduled to complete in the second ...

NVS' first-quarter earnings and sales beat estimates. Based on the strong momentum of its key drugs, the company raises its ...

Novartis shareholders vote in favour of Sandoz spin-off Novartis shareholders on Friday voted in favour of spinning off the Swiss company's generic-drugs business Sandoz, with investors holding 99 ...

NVS' first-quarter performance has likely benefited from strong growth in Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix and ...

The peculiarity of the situation is that Novartis is now unable to recoup biosimilars — since the separation of Sandoz ... cutting off everything that does not relate to innovative pharma ...

Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...

in place to further strengthen Sandoz balance sheet and liquidity New facility replaces initial and unutilized USD 1.25 billion RCF, in place since spin-off in 2023 Dual-tranche CHF 400m and ...

Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility New USD 2.0 billion multi-currency revolving credit ...

Morningstar brands and products Company Portfolio ...

Unfortunately you've used all of your gifts this month. Your counter will reset on the first day of next month. GlobeNewswire, Inc.